全文获取类型
收费全文 | 37104篇 |
免费 | 3064篇 |
国内免费 | 187篇 |
专业分类
耳鼻咽喉 | 411篇 |
儿科学 | 1252篇 |
妇产科学 | 846篇 |
基础医学 | 4394篇 |
口腔科学 | 702篇 |
临床医学 | 3647篇 |
内科学 | 7793篇 |
皮肤病学 | 617篇 |
神经病学 | 3005篇 |
特种医学 | 1128篇 |
外科学 | 5465篇 |
综合类 | 842篇 |
一般理论 | 28篇 |
预防医学 | 2760篇 |
眼科学 | 1458篇 |
药学 | 2815篇 |
1篇 | |
中国医学 | 135篇 |
肿瘤学 | 3056篇 |
出版年
2023年 | 288篇 |
2022年 | 458篇 |
2021年 | 1027篇 |
2020年 | 622篇 |
2019年 | 921篇 |
2018年 | 1029篇 |
2017年 | 755篇 |
2016年 | 856篇 |
2015年 | 981篇 |
2014年 | 1322篇 |
2013年 | 1644篇 |
2012年 | 2579篇 |
2011年 | 2594篇 |
2010年 | 1437篇 |
2009年 | 1279篇 |
2008年 | 2205篇 |
2007年 | 2148篇 |
2006年 | 1978篇 |
2005年 | 1908篇 |
2004年 | 1822篇 |
2003年 | 1565篇 |
2002年 | 1419篇 |
2001年 | 1156篇 |
2000年 | 1038篇 |
1999年 | 891篇 |
1998年 | 340篇 |
1997年 | 251篇 |
1996年 | 226篇 |
1995年 | 225篇 |
1994年 | 199篇 |
1993年 | 185篇 |
1992年 | 529篇 |
1991年 | 487篇 |
1990年 | 447篇 |
1989年 | 409篇 |
1988年 | 369篇 |
1987年 | 341篇 |
1986年 | 335篇 |
1985年 | 331篇 |
1984年 | 229篇 |
1983年 | 207篇 |
1982年 | 142篇 |
1981年 | 105篇 |
1980年 | 112篇 |
1979年 | 161篇 |
1978年 | 95篇 |
1977年 | 103篇 |
1976年 | 71篇 |
1974年 | 85篇 |
1973年 | 72篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
971.
Miguel Verbitsky Simone Sanna-Cherchi David A. Fasel Brynn Levy Krzysztof Kiryluk Matthias Wuttke Alison G. Abraham Frederick Kaskel Anna K?ttgen Bradley A. Warady Susan L. Furth Craig S. Wong Ali G. Gharavi 《The Journal of clinical investigation》2015,125(5):2171-2178
BACKGROUND. There is frequent uncertainty in the identification of specific etiologies of chronic kidney disease (CKD) in children. Recent studies indicate that chromosomal microarrays can identify rare genomic imbalances that can clarify the etiology of neurodevelopmental and cardiac disorders in children; however, the contribution of unsuspected genomic imbalance to the incidence of pediatric CKD is unknown.METHODS. We performed chromosomal microarrays to detect genomic imbalances in children enrolled in the Chronic Kidney Disease in Children (CKiD) prospective cohort study, a longitudinal prospective multiethnic observational study of North American children with mild to moderate CKD. Patients with clinically detectable syndromic disease were excluded from evaluation. We compared 419 unrelated children enrolled in CKiD to multiethnic cohorts of 21,575 children and adults that had undergone microarray genotyping for studies unrelated to CKD.RESULTS. We identified diagnostic copy number disorders in 31 children with CKD (7.4% of the cohort). We detected 10 known pathogenic genomic disorders, including the 17q12 deletion HNF1 homeobox B (HNF1B) and triple X syndromes in 19 of 419 unrelated CKiD cases as compared with 98 of 21,575 control individuals (OR 10.8, P = 6.1 × 10–20). In an additional 12 CKiD cases, we identified 12 likely pathogenic genomic imbalances that would be considered reportable in a clinical setting. These genomic imbalances were evenly distributed among patients diagnosed with congenital and noncongenital forms of CKD. In the vast majority of these cases, the genomic lesion was unsuspected based on the clinical assessment and either reclassified the disease or provided information that might have triggered additional clinical care, such as evaluation for metabolic or neuropsychiatric disease.CONCLUSION. A substantial proportion of children with CKD have an unsuspected genomic imbalance, suggesting genomic disorders as a risk factor for common forms of pediatric nephropathy. Detection of pathogenic imbalances has practical implications for personalized diagnosis and health monitoring in this population.TRIAL REGISTRATION. ClinicalTrials.gov .FUNDING. This work was supported by the NIH, the National Institutes of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Institute of Child Health and Human Development, and the National Heart, Lung, and Blood Institute. NCT00327860相似文献
972.
973.
974.
975.
976.
977.
S. V. Antunes S. Tangada O. Stasyshyn V. Mamonov J. Phillips N. Guzman‐Becerra A. Grigorian B. Ewenstein W.‐Y. Wong 《Haemophilia》2014,20(1):65-72
Factor replacement therapy for the treatment of moderate to severe haemophilia A and B can be complicated by the production of inhibitory alloantibodies to factor VIII (FVIII) or factor IX. Treatment with the nanofiltered anti‐inhibitor coagulant complex, Factor Eight Inhibitor Bypassing Activity (FEIBA NF), is a key therapeutic option for controlling acute haemorrhages in patients with high‐titre inhibitors or low‐titre inhibitors refractory to replacement therapy. Given the high risk for morbidity and mortality in haemophilia patients with inhibitors to FVIII or FIX, we conducted this Phase 3 prospective study to evaluate whether prophylaxis with FEIBA NF is a safe and effective treatment option. Over a 1‐year period, 17 subjects were treated prophylactically (85 ± 15 U kg?1 every other day) while 19 subjects were treated on demand. The median (IQR) annualized bleeding rate (ABR) during prophylaxis was 7.9 (8.1), compared to 28.7 (32.3) during on‐demand treatment, which amounts to a 72.5% reduction and a statistically significant difference in ABRs between arms (P = 0.0003). Three (17.6%) subjects (ITT) on prophylaxis experienced no bleeding episodes, whereas none treated on demand were bleeding episode‐free. Total utilization of FEIBA NF for the treatment of bleeding episodes was significantly higher during on‐demand therapy than prophylaxis (P = 0.0067). There were no differences in the rates of related adverse events between arms. This study demonstrates that FEIBA prophylaxis significantly reduces all types of bleeding compared with on‐demand treatment, and the safety of prophylaxis is comparable to that of on‐demand treatment. 相似文献
978.
J. Windyga T. Lissitchkov O. Stasyshyn V. Mamonov H. Ghandehari M. Chapman S. Fritsch W.‐Y. Wong B. G. Pavlova B. E. Abbuehl 《Haemophilia》2014,20(5):651-658
Haemostatic management of haemophilia B patients undergoing surgery is critical to patient safety. The aim of this ongoing prospective trial was to investigate the haemostatic efficacy and safety of a recombinant factor IX (rFIX) (Bax326) 1 in previously treated subjects (12–65 years, without history of FIX inhibitors) with severe or moderately severe haemophilia B, undergoing surgical, dental or other invasive procedures. Haemostatic efficacy was assessed according to a predefined scale. Blood loss was compared to the average and maximum blood loss predicted preoperatively. Haemostatic FIX levels were achieved peri‐ and postoperatively in 100% of subjects (n = 14). Haemostasis was ‘excellent’ intraoperatively in all patients and postoperatively in those without a drain, and ‘excellent’ or ‘good’ at the time of drain removal and day of discharge in those with a drain employed. Following the initial dose, the mean FIX activity level rose from 6.55% to 107.58% for major surgeries and from 3.60% to 81.4% for minor surgeries. Actual vs. predicted blood loss matched predicted intraoperative blood loss but was equal to or higher than (but less than 150%) the maximum predicted postoperative blood loss reflecting the severity of procedure and FIX requirements. There were no related adverse events, severe allergic reactions or thrombotic events. There was no evidence that BAX326 increased the risk of inhibitor or binding antibody development to FIX. BAX326 was safe and effective for peri‐operative management of 14 subjects with severe and moderately severe haemophilia B. 相似文献
979.
Chronic hepatitis B is one of the leading causes of cirrhosis and hepatocellular carcinoma globally. At present, seven drugs, including two interferons and five oral nucleos(t)ide analogues (NAs), have been approved for the treatment of chronic hepatitis B. Interferon works by immunomodulation, but is successful in less than a third of treated patients and is a relatively weak antiviral. NAs directly suppress the hepatitis B virus but have limited durability. Based on current data, combination of NA and interferon results in greater viral suppression but does not translate to off‐treatment sustained response. Concomitant or sequential treatment also does not make a difference. Combining telbivudine and interferon also runs the risk of severe peripheral neuropathy. On the other hand, interferon switch or additional therapy in patients well controlled with NAs appears to improve the durability of off‐treatment response. This article reviews current data on interferon and NA combination and discusses potential future developments. 相似文献